Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/170258
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

AuthorsEngel, Tobías; Gómez-Sintes, Raquel CSIC ORCID ; Alves, Mariana; Jiménez-Mateos, Eva María; Fernández-Nogales, Marta; Sanz-Rodríguez, Amaya; Morgan, James; Beamer, Edward; Rodríguez-Matellán, Alberto G.; Dunleavy, Mark; Takanori, Sano; Ávila, Jesús CSIC ORCID ; Medina, Miguel CSIC ORCID; Hernández Pérez, Félix; Lucas, José Javier CSIC ORCID; Henshall, David C.
Issue Date20-Sep-2018
PublisherNature Publishing Group
CitationCell Death & Disease 9(10):969 (2018)
AbstractGlycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3β isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases. Recent studies have also linked GSK-3 dysregulation to neuropathological outcomes in epilepsy. To date, however, there has been no genetic evidence for the involvement of GSK-3 in seizure-induced pathology. Status epilepticus (prolonged, damaging seizure) was induced via a microinjection of kainic acid into the amygdala of mice. Studies were conducted using two transgenic mouse lines: a neuron-specific GSK-3β overexpression and a neuron-specific dominant-negative GSK-3β (GSK-3β-DN) expression in order to determine the effects of increased or decreased GSK-3β activity, respectively, on seizures and attendant pathological changes in the hippocampus. GSK-3 inhibitors were also employed to support the genetic approach. Status epilepticus resulted in a spatiotemporal regulation of GSK-3 expression and activity in the hippocampus, with decreased GSK-3 activity evident in non-damaged hippocampal areas. Consistent with this, overexpression of GSK-3β exacerbated status epilepticus-induced neurodegeneration in mice. Surprisingly, decreasing GSK-3 activity, either via overexpression of GSK-3β-DN or through the use of specific GSK-3 inhibitors, also exacerbated hippocampal damage and increased seizure severity during status epilepticus. In conclusion, our results demonstrate that the brain has limited tolerance for modulation of GSK-3 activity in the setting of epileptic brain injury. These findings caution against targeting GSK-3 as a treatment strategy for epilepsy or other neurologic disorders where neuronal hyperexcitability is an underlying pathomechanism.
Description14 p.-5 fig.
Publisher version (URL)https://doi.org/10.1038/s41419-018-0963-5
URIhttp://hdl.handle.net/10261/170258
DOI10.1038/s41419-018-0963-5
E-ISSN2041-4889
Appears in Collections:(CIB) Artículos
(CBM) Artículos




Files in This Item:
File Description SizeFormat
Cell Death & Disease 2018.pdfArtículo principal4,87 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

13
checked on Jul 3, 2022

SCOPUSTM   
Citations

15
checked on Jul 2, 2022

WEB OF SCIENCETM
Citations

18
checked on Jun 29, 2022

Page view(s)

397
checked on Jul 6, 2022

Download(s)

182
checked on Jul 6, 2022

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.